Kristopher A. Sarosiek, Ph.D. - Publications

2009 University of Miami, Coral Gables, FL 
Oncology, Pharmacology, Cell Biology

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Inde Z, Croker BA, Yapp C, Joshi GN, Spetz J, Fraser C, Qin X, Xu L, Deskin B, Ghelfi E, Webb G, Carlin AF, Zhu YP, Leibel SL, Garretson AF, ... ... Sarosiek KA, et al. Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. Science Advances. 7. PMID 34407940 DOI: 10.1126/sciadv.abf8609  1
2021 Daniels VW, Zoeller JJ, van Gastel N, McQueeney KE, Parvin S, Potter DS, Fell GG, Ferreira VG, Yilma B, Gupta R, Spetz J, Bhola PD, Endress JE, Harris IS, Carrilho E, ... Sarosiek KA, et al. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Science Signaling. 14. PMID 34103421 DOI: 10.1126/scisignal.abc7405  1
2020 Inde Z, Yapp C, Joshi GN, Spetz J, Fraser C, Deskin B, Ghelfi E, Sodhi C, Hackam D, Kobzik L, Croker B, Brownfield D, Jia H, Sarosiek KA. Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 disease severity. Biorxiv : the Preprint Server For Biology. PMID 32935109 DOI: 10.1101/2020.09.13.276923  1
2020 Huang S, Xiong J, Vieira CLZ, Blomberg AJ, Gold DR, Coull BA, Sarosiek K, Schwartz JD, Wolfson JM, Li J, Koutrakis P. Short-term exposure to ambient particle gamma radioactivity is associated with increased risk for all-cause non-accidental and cardiovascular mortality. The Science of the Total Environment. 721: 137793. PMID 32172126 DOI: 10.1016/J.Scitotenv.2020.137793  0.01
2020 Gaglia G, Rashid R, Yapp C, Joshi GN, Li CG, Lindquist SL, Sarosiek KA, Whitesell L, Sorger PK, Santagata S. HSF1 phase transition mediates stress adaptation and cell fate decisions. Nature Cell Biology. PMID 32015439 DOI: 10.1038/S41556-019-0458-3  0.01
2019 Rubio L, Pyrgiotakis G, Beltran-Huarac J, Zhang Y, Gaurav J, Deloid G, Spyrogianni A, Sarosiek KA, Bello D, Demokritou P. Safer-by-design flame-sprayed silicon dioxide nanoparticles: the role of silanol content on ROS generation, surface activity and cytotoxicity. Particle and Fibre Toxicology. 16: 40. PMID 31665028 DOI: 10.1186/S12989-019-0325-1  0.01
2019 Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Sarosiek KA, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243  1
2019 Lossos C, Liu Y, Kolb KE, Christie AL, van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, ... ... Sarosiek KA, et al. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. Cancer Discovery. PMID 31040105 DOI: 10.1158/2159-8290.Cd-18-1393  1
2019 Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature Reviews. Molecular Cell Biology. PMID 30655609 DOI: 10.1038/S41580-018-0089-8  1
2019 Spetz J, Presser AG, Sarosiek KA. T Cells and Regulated Cell Death: Kill or Be Killed. International Review of Cell and Molecular Biology. 342: 27-71. PMID 30635093 DOI: 10.1016/Bs.Ircmb.2018.07.004  0.01
2018 Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, ... ... Sarosiek KA, et al. Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer. Cancer Discovery. PMID 30254092 DOI: 10.1158/2159-8290.Cd-18-0277  1
2018 McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. PMID 30220459 DOI: 10.1016/J.Cell.2018.08.038  0.01
2018 Spetz J, Moslehi J, Sarosiek K. Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment. Current Treatment Options in Cardiovascular Medicine. 20: 31. PMID 29556748 DOI: 10.1007/S11936-018-0627-X  0.01
2018 Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nature Cell Biology. PMID 29531308 DOI: 10.1038/S41556-018-0054-Y  1
2017 Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, et al. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications. 8: 1123. PMID 29066722 DOI: 10.1038/S41467-017-01079-1  1
2017 Sarosiek K. Epigenetics make transient states of cancer therapy resistance permanent. Science Translational Medicine. 9. PMID 28659441 DOI: 10.1126/Scitranslmed.Aan6729  0.01
2017 Sarosiek K. Chemotherapy-treated cells go up in flames. Science Translational Medicine. 9. PMID 28515339 DOI: 10.1126/Scitranslmed.Aan4289  0.01
2017 Sarosiek K. Double trouble for CML. Science Translational Medicine. 9. PMID 28381535 DOI: 10.1126/Scitranslmed.Aan2773  0.01
2017 Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis. Cancer Letters. PMID 28259821 DOI: 10.1016/J.Canlet.2017.02.028  1
2017 Crombie J, Lossos C, Sarosiek K, Christie AL, Fraser C, Bhatt S, Deng J, Davids MS, Weinstock DM, Letai A. Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma Blood. 130: 2764-2764. DOI: 10.1182/Blood.V130.Suppl_1.2764.2764  1
2016 Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, et al. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. PMID 28017613 DOI: 10.1016/J.Ccell.2016.11.011  1
2016 Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SW, Gautier F, Juin PP. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Reports. 17: 3347-3358. PMID 28009301 DOI: 10.1016/J.Celrep.2016.11.064  1
2016 Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, ... Sarosiek KA, et al. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports. 17: 2367-2381. PMID 27880910 DOI: 10.1016/J.Celrep.2016.10.077  0.01
2016 Bhatt S, Sarosiek KA, Lossos IS. Interleukin 21 - its potential role in the therapy of B-cell lymphomas. Leukemia & Lymphoma. 1-13. PMID 27405876 DOI: 10.1080/10428194.2016.1201568  1
2016 Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7: 11589. PMID 27199251 DOI: 10.1038/Ncomms11589  1
2016 Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy with BH3 mimetics: recent successes, current challenges and future promise. The Febs Journal. PMID 26996748 DOI: 10.1111/Febs.13714  1
2016 Pen JL, Laurent M, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou J, Letaï A, Braun F, Juin P. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL Cell Death and Disease. 7: 0. PMID 26844698 DOI: 10.1038/Cddis.2015.400  0.01
2015 Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 126: 1555-64. PMID 26194763 DOI: 10.1182/Blood-2015-01-624585  1
2015 Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042  1
2015 Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma Blood. 126: 1555-1564. DOI: 10.1182/blood-2015-01-624585  1
2015 Sarosiek KA, Karst A, Winter P, Sorrentino A, Bandyopadhyay S, Goga A, Wood KC, Drapkin R, Letai A. Abstract 970: Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation Cancer Research. 75: 970-970. DOI: 10.1158/1538-7445.Am2015-970  1
2015 Sarosiek KA, Ziller M, Fraser C, Bhola P, Ryan J, Deng J, Jian B, Goldenberg M, Madsen J, Carrasco R, Robinson S, Moslehi J, Letai A. Abstract 4728: Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity Cancer Research. 75: 4728-4728. DOI: 10.1158/1538-7445.Am2015-4728  1
2014 Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Science Signaling. 7: ra122. PMID 25538080 DOI: 10.1126/Scisignal.2005301  1
2014 Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Research. 74: 3146-56. PMID 24675361 DOI: 10.1158/0008-5472.Can-13-3728  1
2013 Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proceedings of the National Academy of Sciences of the United States of America. 110: 17041-6. PMID 24085845 DOI: 10.1073/Pnas.1305170110  1
2013 Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Molecular Cell. 51: 751-65. PMID 24074954 DOI: 10.1016/J.Molcel.2013.08.048  1
2013 Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends in Cell Biology. 23: 612-9. PMID 24060597 DOI: 10.1016/J.Tcb.2013.08.003  1
2013 Bhatt S, Sarosiek KA, Lossos IS. Abstract LB-328: Preclinical activity of interleukin 21 in mantle cell lymphoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-328  1
2013 Patel LG, Paranal RM, Ryan J, Sarosiek K, Bradner JE, Letai A. Abstract 4610: Small molecule inhibitors of membrane-bound MCL-1 and BCL-2. Cancer Research. 73: 4610-4610. DOI: 10.1158/1538-7445.Am2013-4610  1
2013 Johnson N, Johnson SF, Wang Y, Bernhardy A, Yao W, Choi Y, Capelletti M, Sarosiek K, Moreau L, Chowdhury D, Liu J, D'Andrea A, Miron A, Wickramanayake A, Harrell M, et al. Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C74  0.01
2012 Qi L, Xu C, Sarosiek K, Ligon A, Rodig S, Wong K, Letai A, Shapiro GI. Abstract 2016: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibitionin vitroandin vivo Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2012-2016  1
2011 Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727  1
2011 Qi L, Xu C, Sarosiek KA, Ligon AH, Rodig SJ, Wong K, Letai AG, Shapiro GI. Abstract LB-22: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibition in vitro and in vivo Cancer Research. 72: 2016-2016. DOI: 10.1158/1538-7445.Am2011-Lb-22  0.01
2010 Jiang X, Lu X, McNamara G, Liu X, Cubedo E, Sarosiek KA, Sánchez-García I, Helfman DM, Lossos IS. HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. Blood. 116: 5217-27. PMID 20844236 DOI: 10.1182/Blood-2010-04-281568  1
2010 Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 107: 13069-74. PMID 20615981 DOI: 10.1073/Pnas.1002985107  1
2010 Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 115: 570-80. PMID 19965678 DOI: 10.1182/Blood-2009-08-239996  1
2009 Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. British Journal of Haematology. 147: 308-18. PMID 19694722 DOI: 10.1111/J.1365-2141.2009.07851.X  1
2009 Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, Tibshirani R, Lossos IS. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 113: 3754-64. PMID 19047678 DOI: 10.1182/Blood-2008-10-184077  1
2008 Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood. 112: 4098-108. PMID 18716132 DOI: 10.1182/Blood-2008-03-148726  1
2007 Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Molecular and Cellular Biology. 27: 2166-79. PMID 17210636 DOI: 10.1128/Mcb.01234-06  1
Show low-probability matches.